Department of Otolaryngology, Head and Neck Surgery, SUNY Upstate Medical University, Syracuse, New York, USA.
Curr Opin Otolaryngol Head Neck Surg. 2020 Aug;28(4):258-262. doi: 10.1097/MOO.0000000000000633.
To provide an overview of recently published articles covering melanoma management of the head and neck region.
Melanoma management represents a rapidly evolving field. The advent of immunotherapy has led to significant changes in diagnosis, treatment, and surveillance for these patients. Invasive interventions including completion lymph node dissection have been largely replaced with increased surveillance driven by robust data showing no significant difference in overall survival. Studies have explored various treatment regimens that offer improved outcomes with the least adverse events, with a recent trend towards neoadjuvant therapy. Research has also shifted towards better understanding genetics and biomarkers that influence response to these medications. The best means to both identify and monitor these changes is being explored. As our understanding of this complex disease process continues to grow, prognosis in patients suffering with melanoma should continue to improve.
The expansion of immunotherapy use in melanoma management has led to significantly improved prognosis in diagnosed patients. Present research is largely focused on better understanding the ideal patient populations, dosing, and surveillance for these therapies. Data from these studies will be crucial in better staging and treating patients with melanoma.
提供最近发表的涵盖头颈部黑素瘤管理的文章概述。
黑素瘤的管理代表了一个快速发展的领域。免疫疗法的出现导致了这些患者的诊断、治疗和监测发生了重大变化。包括完成淋巴结清扫术在内的侵袭性干预措施已基本被大量数据显示总生存无显著差异的强化监测所取代。研究探索了各种治疗方案,这些方案在不良反应最少的情况下提供了更好的结果,最近有向新辅助治疗的趋势。研究还转向更好地理解影响这些药物反应的遗传和生物标志物。正在探索识别和监测这些变化的最佳方法。随着我们对这种复杂疾病过程的理解不断加深,患有黑素瘤的患者的预后应该会继续改善。
免疫疗法在黑素瘤管理中的应用扩大导致了诊断患者的预后显著改善。目前的研究主要集中在更好地了解这些疗法的理想患者人群、剂量和监测上。这些研究的数据将对更好地分期和治疗黑素瘤患者至关重要。